Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects
- 315 Downloads
Atypical antipsychotic drugs such as olanzapine induce weight gain and metabolic changes associated with the development of type 2 diabetes. The mechanisms underlying these metabolic side-effects are unknown at the moment. In this study, we investigated the metabolic changes induced by a chronic treatment, as well as the influence of a preceding chronic treatment on the acute effects of olanzapine on glucose metabolism. The effect of chronic olanzapine treatment (±6.5 mg/kg/day, administered via drinking water) on body weight, locomotor activity, body temperature, fat distribution and energy expenditure was investigated in male rats. After 5 weeks, the animals received an acute olanzapine challenge (intragastric, IG) at 3 mg/kg/h during 160 min to investigate the acute effects of olanzapine on glucose metabolism. Chronic olanzapine-treated animals showed a slight decrease in nocturnal body temperature, and increased perirenal fat pad weights as well as plasma leptin. In addition, chronic olanzapine-treated animals showed hyperinsulinaemia with unchanged blood glucose concentrations. The acute challenge with IG olanzapine elevated blood glucose levels and endogenous glucose production in control animals, but not in chronic olanzapine-pre-treated rats. Chronic olanzapine-treated animals also showed reduced locomotor activity and a higher respiratory exchange ratio. Thus, chronic treatment with olanzapine in rats causes desensitization to its acute effects on glucose metabolism but promotes adiposity probably due to a shift from lipids to carbohydrates as an energy source. Chronic exposure to olanzapine changes body fat distribution and insulin sensitivity in an unfavourable direction, but it is still unclear what the primary mechanism is.
KeywordsBody fat composition Energy expenditure Glucose metabolism Locomotor activity Respiratory exchange ratio Food intake
The project was founded by a grant of Top Institute Pharma (TIPharma; T2-105). TIPharma had no role in study design, collection, analyses and interpretation of data, in writing the report and in the decision to submit the article for publication.
Conflict of interest
All authors declare that they have no conflict of interest.
- Ackermans MT, Pereira Arias AM, Bisschop PH, Endert E, Sauerwein HP, Romijn JA (2001) The quantification of gluconeogenesis in healthy men by (2)H2O and [2-(13)C]glycerol yields different results: rates of gluconeogenesis in healthy men measured with (2)H2O are higher than those measured with [2-(13)C]glycerol. J Clin Endocrinol Metab 86:2220–2226PubMedGoogle Scholar
- Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, Joyal JL, Lynch CJ (2010) Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry. doi: 10.1038/mp.2010.33 PubMedCentralPubMedGoogle Scholar
- Albaugh VL, Vary TC, Ilkayeva O, Wenner BR, Maresca KP, Joyal JL, Breazeale S, Elich TD, Lang CH, Lynch CJ (2012) Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. Schizophr Bull. doi: 10.1093/schbul/sbq053 PubMedGoogle Scholar
- Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369–377. doi: 10.1002/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2–6 PubMedCrossRefGoogle Scholar
- Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A, Remington G (2008a) Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 28:494–499. doi: 10.1097/JCP.0b013e318184b4c5 PubMedCrossRefGoogle Scholar
- Davey KJ, O’Mahony SM, Schellekens H, O’Sullivan O, Bienenstock J, Cotter PD, Dinan TG, Cryan JF (2012) Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl) 221:155–169. doi: 10.1007/s00213-011-2555-2 CrossRefGoogle Scholar
- Girault EM, Alkemade A, Foppen E, Ackermans MT, Fliers E, Kalsbeek A (2012) Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance. PLoS One 7:e43244. doi: 10.1371/journal.pone.0043244 PubMedCentralPubMedCrossRefGoogle Scholar
- Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H (2007) Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32:289–297. doi: 10.1038/sj.npp.1301209 PubMedCrossRefGoogle Scholar
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223. doi: 10.1056/NEJMoa051688 PubMedCrossRefGoogle Scholar
- Liebig M, Gossel M, Pratt J, Black M, Haschke G, Elvert R, Juretschke HP, Neumann-Haefelin C, Kramer W, Herling AW (2010) Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring) 18:1952–1958. doi: 10.1038/oby.2010.17 CrossRefGoogle Scholar
- Llorente-Berzal A, Mela V, Borcel E, Valero M, Lopez-Gallardo M, Viveros MP, Marco EM (2012) Neurobehavioral and metabolic long-term consequences of neonatal maternal deprivation stress and adolescent olanzapine treatment in male and female rats. Neuropharmacology 62:1332–1341. doi: 10.1016/j.neuropharm.2011.07.031 PubMedCrossRefGoogle Scholar
- McNamara RK, Jandacek R, Rider T, Tso P, Cole-Strauss A, Lipton JW (2011) Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity. Schizophr Res 129:66–73. doi: 10.1016/j.schres.2011.03.016 PubMedCentralPubMedCrossRefGoogle Scholar
- Minet-Ringuet J, Even PC, Goubern M, Tome D, de Beaurepaire R (2006) Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 46:254–262. doi: 10.1016/j.appet.2006.01.008 PubMedCrossRefGoogle Scholar
- Smith GC, Chaussade C, Vickers M, Jensen J, Shepherd PR (2008) Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 51:2309–2317. doi: 10.1007/s00125-008-1152-3 PubMedCrossRefGoogle Scholar
- Terry AV Jr, Warner SE, Vandenhuerk L, Pillai A, Mahadik SP, Zhang G, Bartlett MG (2008) Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats. Neuroscience 156:1005–1016. doi: 10.1016/j.neuroscience.2008.08.030 PubMedCentralPubMedCrossRefGoogle Scholar
- van der Zwaal EM, Luijendijk MC, Adan RA, la Fleur SE (2008) Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 585:130–136. doi: 10.1016/j.ejphar.2007.11.078 PubMedCrossRefGoogle Scholar